Related references
Note: Only part of the references are listed.Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
Christopher J. Nirschl et al.
CLINICAL CANCER RESEARCH (2013)
The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity
Gunnar Hedlund et al.
PLOS ONE (2013)
Naptumomab estafenatox: a new immunoconjugate
Matthew K. Robinson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
Goran Forsberg et al.
JOURNAL OF IMMUNOTHERAPY (2010)
CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells
Thomas D. Southgate et al.
PLOS ONE (2010)
Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects
Anette Sundstedt et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma
D. M. Shaw et al.
BRITISH JOURNAL OF CANCER (2007)
Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936
JD Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
G Forsberg et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
